On August 8, Hinge Health, Inc. rose 9.84% in regular trading, trading at $87.87/share, with turnover of $92.48 million. The stock continues to rally following strong Q2 results and a significant upward revision to full-year revenue guidance, further supported by Morgan Stanley raising its price target.

The company reported Q2 revenue of $212.8 million, beating the consensus estimate of $201.5 million by approximately 5.6% and representing a 53% year-over-year increase. Adjusted EPS came in at $0.59, in line with expectations. More notably, Hinge Health raised its full-year revenue guidance to $856 million-$860 million, well above the Street estimate of $822.2 million. Q3 revenue guidance of $223 million-$225 million also exceeded the $211.5 million consensus. Morgan Stanley raised its price target from $108 to $117, maintaining an Overweight rating, with the analyst consensus mean target at $100.67.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)